Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Regulatory progress continues, with a positive CHMP recommendation for the ... Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth. Dupixent continues to be a major ...

and as a second-line therapy after patients with PD-L1-positive tumours have progressed despite chemo. In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a ...

At this year's ASCO, positive data was reported from an investigator ... Both are set to be tested alongside Regeneron's PD-1 inhibitor Libtayo (cemiplimab) under an agreement between the two ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

The CBSE Class 10 results for 2025 are expected to be released soon, with students eagerly awaiting their performance. Following exams from February 15 to March 18, 2025, the results are ...

Exoskeletons are currently being tested for their effectiveness in barring at one of Sibanye-Stillwater’s operations as part of the Fall of Ground Action Plan (FoGAP), with positive results so far.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Karnataka School Examination and Assessment Board is set to announce the Karnataka 2nd PUC result 2025 soon, expected by early April. Students who appeared for exams held from March 1 to March 20 ...

Amidst this positive news, Wells Fargo analyst Yanan Zhu upgraded Regulus Therapeutics from Equal Weight to Overweight and raised the price target from $3.00 to $6.00, further buoying investor ...